Edition:
United States

Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

14.75EUR
11:35am EDT
Change (% chg)

€-0.09 (-0.61%)
Prev Close
€14.84
Open
€14.85
Day's High
€14.85
Day's Low
€14.71
Volume
3,244
Avg. Vol
9,001
52-wk High
€17.50
52-wk Low
€8.92

Latest Key Developments (Source: Significant Developments)

Vexim Q2 sales rise to 5.7 million euros
Tuesday, 11 Jul 2017 12:00pm EDT 

July 11 (Reuters) - VEXIM SA ::+23% GROWTH IN SALES IN Q2, UP TO EUR 5.7 MILLION.ANTICIPATES A CONTINUED STRONG GROWTH IN SALES IN SECOND PART OF 2017.  Full Article

Vexim says Anvisa approves Spinejack implants in Brazil
Monday, 29 May 2017 12:00pm EDT 

May 29 (Reuters) - VEXIM SA :VEXIM: ANVISA APPROVES SPINEJACK® IMPLANTS IN BRAZIL.HAS RECEIVED REGULATORY APPROVAL FROM ANVISA(1), BRAZIL'S NATIONAL HEALTH SURVEILLANCE AGENCY, IN ORDER TO COMMERCIALIZE SPINEJACK® IN BRAZIL..VEXIM ESTIMATES THAT BRAZIL ALONE TODAY REPRESENTS A EUR 15 MILLION MARKET IN VERTEBRAL COMPRESSION FRACTURES FIELD..  Full Article

Vexim aims at reaching profitability on full year basis in 2017
Wednesday, 17 May 2017 12:00pm EDT 

May 17 (Reuters) - VEXIM SA ::AIMS AT REACHING PROFITABILITY ON FULL YEAR BASIS IN 2017 AND FUTURE CASH FLOWS SHOULD ALLOW VEXIM TO SELF-FINANCE.  Full Article

Vexim launches Masterflow plus in Germany
Tuesday, 18 Apr 2017 01:00am EDT 

April 18 (Reuters) - Vexim SA ::New product launch in Germany: Masterflow plus, a new product targeted at low energy osteoporotic fractures.  Full Article

Vexim FY operating loss narrows at 3.2 million euros
Wednesday, 22 Mar 2017 02:11am EDT 

Vexim SA : FY operating loss 3.2 million euros ($3.46 million) versus loss of 4.8 million euros year ago . Net loss recorded in 2016, which includes income tax and finance costs of 0.5 million euros, is 2.7 million euros compared to 4.8 million euros in 2015 . Cash position: 9.8 million euros as of December 31st, 2016 (+ 0.3 million euros versus June 30th, 2016) . 2017 objectives: positive net income and operating income throughout the full year . 2017 objectives: perspectives of profitable growth . sales growth of +30 percent to +35 percent (organic) .2017 objectives: US FDA 510(k) filing planned in last quarter for Spinejack.  Full Article

Vexim announces another major step towards SpineJack commercialization in US
Tuesday, 21 Feb 2017 02:00am EST 

Vexim SA : Finalizes recruitment of patients for international clinical study, supporting the 510 (k) regulatory approval application to the FDA .Submission of the regulatory dossier planned by the end of 2017, for a probable launch in the United States in the first half of 2018.  Full Article

Vexim 9M sales rises to €13.3 million euros
Thursday, 13 Oct 2016 02:06am EDT 

Vexim SA :Vexim: +37% sales increase to 13.3 million euros ($14.90 million) as of september 30, 2016 (9 Months).  Full Article

Vexim Q3 revenue up 37 pct at 4.6 mln euros
Tuesday, 12 Jul 2016 12:05pm EDT 

Vexim SA : Q2 revenue 4.6 million euros ($5.1 million) versus 3.4 million euros year ago . H1 revenue 8.6 million euros versus 6.1 million euros year ago .At the end of the Q2 2016, total number of implants sold since launch of the SpineJack came to over 34,300 units.  Full Article

Vexim announces successful private placement of 10.4 mln euros
Thursday, 28 Jan 2016 01:00am EST 

Vexim SA:Announces success of its capital increase through a private placement of 10.4 million euros.Placed 1,269,694 new shares with a nominal value of 0.10 euros at unit price of 8.20 euros.  Full Article

Vexim initiates new clinical study on Spinejack
Tuesday, 12 Jan 2016 02:00am EST 

Vexim SA:Initiates a new clinical study to support safety, efficacy and cost-effectiveness of Spinejack compared to conservative treatment.  Full Article

BRIEF-Vexim Q2 sales rise to 5.7 million euros

* ANTICIPATES A CONTINUED STRONG GROWTH IN SALES IN SECOND PART OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)